Pancreatic Cancer Drug Daraxonrasib Halves Death Risk, Gains US Approval
A groundbreaking oral drug, daraxonrasib (Rasonque), has received U.S. FDA approval for metastatic pancreatic cancer after Phase 3 trials showed it reduced the risk of death by 60% and nearly doubled patients' overall survival time to 13.2 months compared to chemotherapy. This represents a major advancement for one of the deadliest cancers.
Key Highlights
- Daraxonrasib reduced metastatic pancreatic cancer death risk by 60%.
- Patients' median overall survival doubled to 13.2 months.
- The daily oral pill, Rasonque, received US FDA approval.
- Targets previously 'undruggable' RAS mutations in over 90% of cases.
- Phase 3 trial results published in New England Journal of Medicine.
- Offers new hope for patients with limited treatment options.
A significant breakthrough in pancreatic cancer treatment has emerged with the U.S. Food and Drug Administration (FDA) approval of daraxonrasib, an investigational oral drug now marketed under the brand name Rasonque, developed by Revolution Medicines. This approval follows the impressive results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial, which demonstrated that daraxonrasib reduced the risk of death by 60% in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The trial further revealed that patients receiving daraxonrasib achieved a median overall survival (OS) of 13.2 months, nearly double the 6.7 months observed in patients treated with standard chemotherapy.
Pancreatic cancer, particularly metastatic PDAC, is one of the most aggressive and deadliest forms of cancer, with a historically low five-year survival rate, often less than 7%. A major challenge in treating this disease has been the prevalence of RAS mutations, which drive tumor growth in over 90% of PDAC cases and were long considered 'undruggable'. Daraxonrasib, a first-in-class oral RAS(ON) multi-selective inhibitor, works by directly blocking active RAS signaling, targeting these crucial KRAS G12D/G12V/G12R mutations. This mechanism represents a new paradigm in cancer therapy, offering a targeted approach where conventional treatments have largely failed.
The RASolute 302 trial enrolled approximately 500 patients whose metastatic pancreatic cancer had progressed after initial treatment with chemotherapy. In addition to the dramatic improvement in overall survival, daraxonrasib also significantly extended progression-free survival (PFS), doubling it to 7.2 months compared to 3.6 months for chemotherapy in the intent-to-treat (ITT) population. Patients treated with daraxonrasib also experienced a higher rate of tumor shrinkage, with about 33% achieving an objective response in the RAS G12 population compared to 11% in the chemotherapy group. Crucially, the drug was generally well-tolerated with a manageable safety profile, and patients reported slower worsening of pain and better preservation of quality of life over time.
The results of the RASolute 302 trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. The FDA had previously granted daraxonrasib 'Breakthrough Therapy' designation, accelerating its review process, leading to its early approval in August 2026. This approval provides a critical new option for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
The global impact of this drug is immense. While the initial approval is in the U.S., Revolution Medicines plans to submit these data to other global regulatory agencies. For countries like India, where pancreatic cancer remains a significant health challenge with limited advanced treatment options, the availability of daraxonrasib could be transformative. Indian hospitals currently offer various treatments for pancreatic cancer, including surgery, chemotherapy, radiation therapy, and targeted therapy. The introduction of a highly effective targeted oral therapy would augment existing treatment protocols and provide renewed hope for patients and their families. Experts have hailed this development as one of the most significant breakthroughs for pancreatic cancer in decades, signaling a shift in the fight against this notoriously difficult disease. The ability to specifically target RAS mutations opens doors for further research and development of similar therapies for other RAS-driven cancers.
Regarding the source, 'The Clinical Trial Vanguard,' while not a widely recognized major news outlet, the claims made in the title about 'Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial' are thoroughly corroborated by multiple highly reputable medical and news sources, including official company announcements, major medical journals, and leading news organizations. Therefore, the information itself is accurate and well-verified.
Frequently Asked Questions
What is daraxonrasib (Rasonque) and what does it treat?
Daraxonrasib, marketed as Rasonque, is a new oral drug developed by Revolution Medicines. It is a first-in-class RAS(ON) multi-selective inhibitor approved for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have previously undergone at least one systemic therapy or are not candidates for multiagent systemic therapy. It works by targeting RAS mutations, which are key drivers of pancreatic cancer.
How effective is daraxonrasib compared to existing treatments for pancreatic cancer?
In Phase 3 clinical trials (RASolute 302), daraxonrasib demonstrated significant efficacy, reducing the risk of death by 60% compared to standard chemotherapy. It nearly doubled the median overall survival for patients with metastatic pancreatic cancer, from 6.7 months with chemotherapy to 13.2 months with daraxonrasib. It also significantly improved progression-free survival and quality of life.
When and where was daraxonrasib approved?
Daraxonrasib (Rasonque) received approval from the U.S. Food and Drug Administration (FDA) on August 26, 2026. The drug had previously been granted 'Breakthrough Therapy' designation to expedite its review due to its significant potential benefit for patients.
What are RAS mutations and why is targeting them significant for pancreatic cancer?
RAS mutations are genetic alterations that lead to overactive RAS proteins, which are critical drivers of uncontrolled cell growth and division in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases. Historically, these mutations were considered 'undruggable.' Daraxonrasib's ability to directly inhibit active RAS signaling represents a major scientific breakthrough, offering a targeted treatment for a vast majority of pancreatic cancer patients.
What does this breakthrough mean for pancreatic cancer patients in India?
While daraxonrasib is currently approved in the U.S., its global trial and planned submissions to other regulatory agencies signify its potential availability worldwide, including in India. For Indian patients battling metastatic pancreatic cancer, this drug offers significant hope for extended survival and improved quality of life, especially given the aggressive nature of the disease and the limited effective treatment options currently available.
